Who are Anti-IL17's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Taltz, Cosentyx, Secukinumab Auto-Injector, Proactive TDM-based dosing of ixekizumab, Vunakizumab (IL-17A inhibitor), Ixekizumab Prefilled Syringe.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/anti-il17.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Anti-IL17 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anti-IL17 (Anti-IL17) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anti-inflammatory. Area: Immunology.

phase 2 Anti-inflammatory IL-17 Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Anti-IL17 (Anti-IL17) — Prof. Dr. Stephan Weidinger. IL-17 inhibitor

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Anti-IL17 TARGET	Anti-IL17	Prof. Dr. Stephan Weidinger	phase 2	Anti-inflammatory	IL-17
Taltz	ixekizumab	Eli Lilly	marketed	Interleukin-17A antagonist	Interleukin 17A (IL-17A) cytokine	2016-01-01
Cosentyx	secukinumab	Novartis	marketed	IL-17A antagonist	Interleukin-17A (IL-17A)	2015-01-01
Secukinumab Auto-Injector	Secukinumab Auto-Injector	University of Pennsylvania	marketed	IL-17A inhibitor (monoclonal antibody)	IL-17A
Proactive TDM-based dosing of ixekizumab	Proactive TDM-based dosing of ixekizumab	University Hospital, Ghent	marketed	IL-17A inhibitor; monoclonal antibody	IL-17A
Vunakizumab (IL-17A inhibitor)	Vunakizumab (IL-17A inhibitor)	Fujian Cancer Hospital	marketed	IL-17A inhibitor (monoclonal antibody)	IL-17A
Ixekizumab Prefilled Syringe	Ixekizumab Prefilled Syringe	Eli Lilly and Company	marketed	IL-17A inhibitor (monoclonal antibody)	IL-17A

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anti-inflammatory class)

A. Vogel AG · 1 drug in this class
Bausch & Lomb Incorporated · 1 drug in this class
Marie Hudson, MD · 1 drug in this class
Organon and Co · 1 drug in this class
Panacea Biotec Ltd · 1 drug in this class
Prof. Dr. Stephan Weidinger · 1 drug in this class
Salus Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Anti-IL17 — Competitive Intelligence Brief. https://druglandscape.com/ci/anti-il17. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing